Friedreich ataxia (FA) is a rare inherited disease that affects the nervous system. It is usually diagnosed in childhood and affects about 5,000 people in the U.S. It causes a loss of muscle control.
Today, we celebrate the impact of an engaged patient community, and we are grateful to the FDA and Reata for working together on the approval of SKYCLARYS, the first therapy approved in the United ...
Friedreich’s ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its ...
CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended ...
Please provide your email address to receive an email when new articles are posted on . Skyclarys was approved in the U.S. for Friedreich’s ataxia in 2023. Approval was based on positive results from ...
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the ...
Cerebellar ataxia results from dysfunction of the cerebellum, which is part of the brain that helps regulate and control movement and balance. People may experience changes in gait, speech, and eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results